SCHEMBL20768510

SCHEMBL20768510

CCc1c(C(=O)O)cccc1C1(NC(=O)c2cc3c(Cl)c(Cl)ccc3n2C)CCCNC1

nearest known ligand 0.49

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PHGDH O43175 17/20 0.49
▸ SLC6A9 P48067 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19343472 0.82 PHGDH (0.59) PHGDHSLC6A9
SCHEMBL20768402 0.81 PHGDH (0.59) PHGDHSLC6A9
SCHEMBL25153798 0.80 PHGDH (0.52) PHGDHSLC6A9
SCHEMBL26373067 0.78 PHGDH (0.52) PHGDHSLC6A9
SCHEMBL19344099 0.77 PHGDH (0.48) PHGDH
SCHEMBL19343490 0.77 PHGDH (0.49) PHGDHSLC6A9
SCHEMBL19343380 0.77 PHGDH (0.49) PHGDHSLC6A9
SCHEMBL19343450 0.77 PHGDH (0.61) PHGDHSLC6A9
SCHEMBL20768403 0.75 PHGDH (0.52) PHGDHSLC6A9
SCHEMBL20768404 0.75 PHGDH (0.62) PHGDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-10-05 — — US disclosed
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2023-01-12 — — US disclosed
EP-3884939-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF Raze Therapeutics, Inc. (US) 2021-09-29 — — EP disclosed
US-10954220-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof RAZE THERAPEUTICS, INC. (US) 2021-03-23 — — US disclosed
US-20190071431-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. 2019-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230009122-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD PHGDH 1/4885SLC6A9 1886/4885
US-20190071431-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD PHGDH 1/4885SLC6A9 1886/4885
US-10954220-B2 3-phosphoglycerate dehydrogenase inhibitors and uses thereof PHGDH, G6PD, PGD PHGDH 1/4885SLC6A9 1886/4885
US-20230312536-A1 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF PHGDH, G6PD, PGD PHGDH 1/4885SLC6A9 1886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback